A Study of Intratumoral/Intralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Malignancies (V938-001)
Clinical trial NCT04135352 · TERMINATED
Trial details
- NCT number
- NCT04135352
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-11-04
- Primary completion
- 2022-08-24
- Enrollment
- 35
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.